BG105082A - 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists - Google Patents

4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Info

Publication number: BG105082A
Authority: BG; Bulgaria
Prior art keywords: receptor antagonists; subtype; nmda receptor; selective nmda; benzyl piperidine
Prior art date: 1998-06-26

Application number

BG105082A

Other languages

Bulgarian (bg)

English (en)

Inventor

Jonathan Wright

Suzanne Kesten

Ravindra UPSANI

Nancy LAN

Original Assignee

Warner-Lambert Company

CoCENSYS, INC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-26

Filing date

2000-12-21

Publication date

2001-09-28

2000-12-21 Application filed by Warner-Lambert Company, CoCENSYS, INC filed Critical Warner-Lambert Company

2001-09-28 Publication of BG105082A publication Critical patent/BG105082A/xx

Links

229940127523 NMDA Receptor Antagonists Drugs 0.000 title abstract 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BG105082A 1998-06-26 2000-12-21 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists BG105082A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9091498P	1998-06-26	1998-06-26
PCT/US1999/014291 WO2000000197A1 (en)	1998-06-26	1999-06-25	4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Publications (1)

Publication Number	Publication Date
BG105082A true BG105082A (en)	2001-09-28

Family

ID=22224939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105082A BG105082A (en)	1998-06-26	2000-12-21	4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists

Country Status (28)

Country	Link
US (1)	US6284774B1 (id)
EP (1)	EP1089735B1 (id)
JP (1)	JP2002519322A (id)
KR (1)	KR20010053170A (id)
CN (1)	CN1304307A (id)
AP (1)	AP2000001949A0 (id)
AT (1)	ATE297207T1 (id)
AU (1)	AU769650B2 (id)
BG (1)	BG105082A (id)
BR (1)	BR9911575A (id)
CA (1)	CA2327888A1 (id)
DE (1)	DE69925730T2 (id)
EA (1)	EA200100058A1 (id)
EE (1)	EE200000778A (id)
ES (1)	ES2244201T3 (id)
HU (1)	HUP0102471A2 (id)
ID (1)	ID28005A (id)
IL (1)	IL138949A0 (id)
IS (1)	IS5667A (id)
NO (1)	NO20006482D0 (id)
NZ (1)	NZ508808A (id)
OA (1)	OA11570A (id)
PE (1)	PE20000728A1 (id)
PL (1)	PL345024A1 (id)
SK (1)	SK19512000A3 (id)
TR (1)	TR200003888T2 (id)
WO (1)	WO2000000197A1 (id)
ZA (1)	ZA200005848B (id)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6476041B1 (en)	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists
UA73749C2 (en) *	1999-11-01	2005-09-15		Diarylenines
EA200200952A1 (ru) *	2000-04-26	2003-02-27	Уорнер-Ламберт Компани	Производные циклогексиламина в качестве селективных антагонистов подтипов nmda-рецепторов
WO2001092204A1 (en) *	2000-06-01	2001-12-06	Warner-Lambert Company	Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
ES2291329T3 (es) *	2000-07-18	2008-03-01	Dainippon Sumitomo Pharma Co., Ltd.	Inhibidores de la recaptacion de serotonina.
IL145584A0 (en)	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment
HU227197B1 (en)	2000-10-24	2010-10-28	Richter Gedeon Nyrt	Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
PL364625A1 (en)	2001-02-23	2004-12-13	Merck & Co, Inc.	N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP1436258A4 (en) *	2001-03-08	2005-03-23	Univ Emory	PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS
WO2002080928A1 (en)	2001-04-03	2002-10-17	Merck & Co., Inc.	N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
CA2381630A1 (en) *	2001-04-23	2002-10-23	Leonard Theodore Meltzer	Method for preventing dyskinesias
ES2312603T3 (es)	2001-07-24	2009-03-01	Richter Gedeon Nyrt	Derivados de piperidina como antagonistas del receptor nmda.
EP1575916B1 (en)	2001-08-31	2013-05-22	The Rockefeller University	Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20060281797A1 (en) *	2001-12-11	2006-12-14	University Of Virginia Patent Foundation	Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) *	2001-12-11	2013-12-04	University Of Virginia Patent Foundation	Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8389578B2 (en)	2004-11-24	2013-03-05	Adamas Pharmaceuticals, Inc	Composition and method for treating neurological disease
EP1827468B1 (en) *	2004-12-23	2012-08-22	Curaxis Pharmaceutical Corporation	Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
WO2007022182A1 (en) *	2005-08-15	2007-02-22	University Of Virginia Patent Foundation	Neurorestoration with r(+) pramipexole
US8518926B2 (en)	2006-04-10	2013-08-27	Knopp Neurosciences, Inc.	Compositions and methods of using (R)-pramipexole
ES2379117T3 (es)	2006-05-16	2012-04-20	Knopp Neurosciences, Inc.	Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
EP2089383B1 (en)	2006-11-09	2015-09-16	Probiodrug AG	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US8524695B2 (en)	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008220785B2 (en)	2007-03-01	2013-02-21	Vivoryon Therapeutics N.V.	New use of glutaminyl cyclase inhibitors
CA2681110A1 (en)	2007-03-14	2008-09-18	Knopp Neurosciences, Inc.	Synthesis of chirally purified substituted benzothiazole diamines
JP5667440B2 (ja)	2007-04-18	2015-02-12	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
KR20100045983A (ko)	2007-06-29	2010-05-04	에모리 유니버시티	신경보호를 위한 ｎｍｄａ 수용체 길항물질
DE102007047737A1 (de) *	2007-10-05	2009-04-30	Merck Patent Gmbh	Piperidin- und Piperazinderivate
TWI410420B (zh) *	2008-02-05	2013-10-01	Dainippon Sumitomo Pharma Co	苄基哌啶化合物
WO2009129497A2 (en) *	2008-04-18	2009-10-22	Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona	Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
KR20110071064A (ko)	2008-08-19	2011-06-28	크놉 뉴로사이언시스 인코포레이티드	(ｒ)-프라미펙솔을 사용하는 조성물 및 방법
HUP0900130A3 (en)	2009-03-03	2012-02-28	Richter Gedeon Nyrt	Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
WO2011016468A1 (ja)	2009-08-04	2011-02-10	大日本住友製薬株式会社	ベンジルピペリジン化合物
SG178279A1 (en)	2009-08-05	2012-03-29	Intra Cellular Therapies Inc	Novel regulatory proteins and inhibitors
JP5934645B2 (ja)	2009-09-11	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
MX365650B (es)	2009-12-02	2019-06-10	Adamas Pharmaceuticals Inc	Composiciones de amantadina y metodos para su uso.
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
JP5688745B2 (ja)	2010-03-10	2015-03-25	プロビオドルグエージー	グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
EP2686313B1 (en)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
MX2014004469A (es)	2011-11-22	2014-08-01	Univ California	Metodos y composiciones para tratar inflamacion y lesion isquemica.
WO2013096816A1 (en)	2011-12-22	2013-06-27	Biogen Idec Ma Inc.	Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en)	2013-02-28	2017-05-30	Knopp Biosciences Llc	Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
US9468630B2 (en)	2013-07-12	2016-10-18	Knopp Biosciences Llc	Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en)	2013-07-12	2025-09-03	Areteia Therapeutics, Inc.	Treating elevated levels of eosinophils and/or basophils
CA2921381A1 (en)	2013-08-13	2015-02-19	Knopp Biosciences Llc	Compositions and methods for treating chronic urticaria
ES2813674T3 (es)	2013-08-13	2021-03-24	Knopp Biosciences Llc	Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
US10752588B2 (en)	2014-12-19	2020-08-25	The Broad Institute, Inc.	Dopamine D2 receptor ligands
WO2016100940A1 (en) *	2014-12-19	2016-06-23	The Broad Institute, Inc.	Dopamine d2 receptor ligands
CA3072764A1 (en)	2017-08-24	2019-02-28	Adamas Pharma, Llc	Amantadine compositions, preparations thereof, and methods of use
ES2812698T3 (es)	2017-09-29	2021-03-18	Probiodrug Ag	Inhibidores de glutaminil ciclasa
WO2020219975A1 (en) *	2019-04-26	2020-10-29	Cytosolve, Inc.	Compositions for improving brain health and memory

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792187A (fr) *	1971-12-03	1973-03-30	Sumitomo Chemical Co	Nouveaux derives d'alkylamines
DE2845537A1 (de)	1978-10-19	1980-04-30	Bayer Ag	Benzimidazolylcarbamidsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
ZA848275B (en) *	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
EP0488959A3 (en)	1990-11-28	1992-08-05	Sandoz Ltd.	New uses of competitive nmda receptor antagonists
JPH05194505A (ja) *	1991-08-09	1993-08-03	Yoshitomi Pharmaceut Ind Ltd	チオフェン化合物
US5192751A (en)	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
JP2959615B2 (ja) *	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
ATE174915T1 (de)	1994-10-31	1999-01-15	Merck Patent Gmbh	Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
AU5271296A (en) *	1995-04-07	1996-10-23	Novo Nordisk A/S	Novel method
ZA9610745B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1998015550A1 (en) *	1996-10-04	1998-04-16	Novo Nordisk A/S	N-substituted azaheterocyclic compounds
DE19643790A1 (de)	1996-10-30	1998-05-07	Merck Patent Gmbh	Benzoxazol-Derivat

1999
- 1999-06-24 PE PE1999000567A patent/PE20000728A1/es not_active Application Discontinuation
- 1999-06-25 CN CN99807087A patent/CN1304307A/zh active Pending
- 1999-06-25 US US09/674,298 patent/US6284774B1/en not_active Expired - Fee Related
- 1999-06-25 ID IDW20002514A patent/ID28005A/id unknown
- 1999-06-25 EE EEP200000778A patent/EE200000778A/xx unknown
- 1999-06-25 TR TR2000/03888T patent/TR200003888T2/xx unknown
- 1999-06-25 AP APAP/P/2000/001949A patent/AP2000001949A0/en unknown
- 1999-06-25 AT AT99931887T patent/ATE297207T1/de not_active IP Right Cessation
- 1999-06-25 EA EA200100058A patent/EA200100058A1/ru unknown
- 1999-06-25 CA CA002327888A patent/CA2327888A1/en not_active Abandoned
- 1999-06-25 SK SK1951-2000A patent/SK19512000A3/sk unknown
- 1999-06-25 HU HU0102471A patent/HUP0102471A2/hu unknown
- 1999-06-25 KR KR1020007014745A patent/KR20010053170A/ko not_active Withdrawn
- 1999-06-25 ES ES99931887T patent/ES2244201T3/es not_active Expired - Lifetime
- 1999-06-25 OA OA1200000347A patent/OA11570A/en unknown
- 1999-06-25 IL IL13894999A patent/IL138949A0/xx unknown
- 1999-06-25 JP JP2000556782A patent/JP2002519322A/ja active Pending
- 1999-06-25 DE DE69925730T patent/DE69925730T2/de not_active Expired - Fee Related
- 1999-06-25 WO PCT/US1999/014291 patent/WO2000000197A1/en not_active Ceased
- 1999-06-25 NZ NZ508808A patent/NZ508808A/xx unknown
- 1999-06-25 AU AU48303/99A patent/AU769650B2/en not_active Ceased
- 1999-06-25 BR BR9911575-1A patent/BR9911575A/pt not_active Application Discontinuation
- 1999-06-25 EP EP99931887A patent/EP1089735B1/en not_active Expired - Lifetime
- 1999-06-25 PL PL99345024A patent/PL345024A1/xx unknown
2000
- 2000-10-16 IS IS5667A patent/IS5667A/is unknown
- 2000-10-19 ZA ZA200005848A patent/ZA200005848B/en unknown
- 2000-12-19 NO NO20006482A patent/NO20006482D0/no not_active Application Discontinuation
- 2000-12-21 BG BG105082A patent/BG105082A/xx unknown

Also Published As

Publication number	Publication date
EP1089735A4 (en)	2002-12-18
AU4830399A (en)	2000-01-17
IL138949A0 (en)	2001-11-25
ID28005A (id)	2001-05-03
EP1089735A1 (en)	2001-04-11
ZA200005848B (en)	2001-12-18
NO20006482L (no)	2000-12-19
US6284774B1 (en)	2001-09-04
AU769650B2 (en)	2004-01-29
JP2002519322A (ja)	2002-07-02
IS5667A (is)	2000-10-16
EP1089735B1 (en)	2005-06-08
HUP0102471A2 (hu)	2002-05-29
NZ508808A (en)	2002-12-20
EA200100058A1 (ru)	2001-08-27
CN1304307A (zh)	2001-07-18
ES2244201T3 (es)	2005-12-01
AP2000001949A0 (en)	2000-12-31
EE200000778A (et)	2002-04-15
CA2327888A1 (en)	2000-01-06
SK19512000A3 (sk)	2001-08-06
PE20000728A1 (es)	2000-08-21
DE69925730D1 (de)	2005-07-14
PL345024A1 (en)	2001-11-19
ATE297207T1 (de)	2005-06-15
OA11570A (en)	2004-07-01
NO20006482D0 (no)	2000-12-19
DE69925730T2 (de)	2006-03-23
BR9911575A (pt)	2001-03-20
TR200003888T2 (tr)	2001-06-21
WO2000000197A1 (en)	2000-01-06
KR20010053170A (ko)	2001-06-25

Publication	Publication Date	Title
BG105082A (en)	2001-09-28	4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective nmda receptor antagonists
HU9503826D0 (en)	1996-02-28	Heterocycles useful as neurokinin antagonists
ZA200108867B (en)	2003-03-26	Piperidine derivatives useful as CCR5 antagonists.
MXPA03003246A (es)	2003-06-06	Derivados de indolina y su uso como ligandos del receptor 5-ht2.
HUP0204587A3 (en)	2004-07-28	6-position substituted indoline, production and use thereof as a medicament
ZA200201788B (en)	2003-08-27	Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
PL353969A1 (en)	2003-12-15	Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
GB9911053D0 (en)	1999-07-14	4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
MXPA04000886A (es)	2004-06-03	Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
MY122391A (en)	2006-04-29	Piperazine derivatives as 5-ht1b antagonists
ZA200110218B (en)	2002-12-12	Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands.
IL138702A0 (en)	2001-10-31	Substituted indolinones, the production thereof and their use as medicaments
MXPA02004701A (es)	2004-09-10	Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
HUP0202880A3 (en)	2003-04-28	Sustained release compositions, process for producing the same and use thereof
AU1667500A (en)	2000-06-26	N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
GEP20043267B (en)	2004-06-25	Adenosine Receptor Antagonists, Methods of Making and Using the Same
ZA200104187B (en)	2002-11-22	1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists.
MXPA03008896A (es)	2003-12-08	Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos.
TR200001102T2 (tr)	2000-08-21	İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
PL353875A1 (en)	2003-12-01	Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
PL351794A1 (en)	2003-06-16	4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
NZ533358A (en)	2007-05-31	3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
AU2548400A (en)	2000-08-29	Novel use of orexin receptor antagonists
ZA200107985B (en)	2002-12-24	Substituted benzimidazole, the production thereof and the use thereof as means against parasitic protozoa.
ZA9810425B (en)	2000-05-15	Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.